Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6556663 | 1.00 | — | — | |
| Methane SCHEMBL27572875 | 0.97 | TSHR (0.88) | — | |
| SCHEMBL19193 | 0.97 | — | — | |
| SCHEMBL21064874 | 0.97 | TSHR (1.00) | — | |
| SCHEMBL4431010 | 0.93 | TSHR (0.93) | — | |
| Methyl Alcohol SCHEMBL584909 | 0.93 | — | — | |
| Ammonia Solution, Strong SCHEMBL5086843 | 0.93 | — | — | |
| Water SCHEMBL1289230 | 0.93 | — | — | |
| SCHEMBL28881770 | 0.93 | — | — | |
| SCHEMBL1278490 | 0.93 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110668952-B | Preparation method of benzphetamine hydrochloride | 安徽贝克制药股份有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-110655466-B | Preparation method of benzphetamine hydrochloride | 安徽贝克制药股份有限公司 | 2023-02-24 | — | — | CN | claimed |
| CN-111018723-B | Preparation and detection method of dapoxetine hydrochloride isomer impurity | 盖天力医药控股集团制药股份有限公司 | 2022-03-08 | — | — | CN | claimed |
| CN-111018723-A | Preparation and detection method of dapoxetine hydrochloride isomer impurity | 盖天力医药控股集团制药股份有限公司 | 2020-04-17 | — | — | CN | claimed |
| CN-110668952-A | Preparation method of benzphetamine hydrochloride | 安徽贝克联合制药有限公司 | 2020-01-10 | — | — | CN | claimed |
| CN-110655466-A | Preparation method of benzphetamine hydrochloride | 安徽贝克联合制药有限公司 | 2020-01-07 | — | — | CN | claimed |
| CN-107445951-A | A kind of preparation method and purposes of sulfuric acid Chinese mugwort Saperconazole diastereoisomer impurity | 上海键合医药科技有限公司 | 2017-12-08 | — | — | CN | claimed |
| CN-101948441-B | Novel preparation method of Erlotinib hydrochloride with crystal form A | JIANGSU SIMCERE PHARM RES CO | 2012-07-25 | — | — | CN | claimed |
| CN-101948441-A | Novel preparation method of Erlotinib hydrochloride with crystal form A | JIANGSU SIMCERE PHARM RES CO | 2011-01-19 | — | — | CN | claimed |
| CN-119431222-A | Method for asymmetrically synthesizing chiral intermediate of ubenimpam | 杭州澳赛诺生物科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-111655709-B | Synthesis of antibacterial aminoglycoside analogs | 轩竹(北京)医药科技有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-11840519-B2 | Process for the synthesis of the sodium salt of 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)-phenyl]methyl]-3,6-dihydro-4-methyl-2.6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]-butanoic acid (elagolix sodium salt) and intermediates of said process | INDUSTRIALE CHIMICA S.R.L. (IT) | 2023-12-12 | — | — | US | disclosed |
| CN-110668952-B | Preparation method of benzphetamine hydrochloride | 安徽贝克制药股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-110655466-B | Preparation method of benzphetamine hydrochloride | 安徽贝克制药股份有限公司 | 2023-02-24 | — | — | CN | disclosed |
| US-6355611-B1 | SODIUM SALT OF PROSTATE SPECIFIC ANTIGEN CONJUGATE COMPOUND; USEFUL IN TREATMENT OF PROSTATE CANCER AND BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010038823-A1 | MICROPARTICLES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN ULTRASOUND DIAGNOSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-08 | — | — | US | disclosed |
| WO-2001030804-A2 | SALT FORM OF A CONJUGATE USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO., INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| WO-2001029065-A1 | PROCESS FOR PREPARING PEPTIDE INTERMEDIATES | MERCK SHARP & DOHME LIMITED (GB) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001028593-A2 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO., INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| CN-1100098-A | 2-amino-4-quinolyl-dihydropyridines, processes for their preparation, and their use | BAYER AG (DE) | 1995-03-15 | — | — | CN | disclosed |